IN2012DN03294A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03294A
IN2012DN03294A IN3294DEN2012A IN2012DN03294A IN 2012DN03294 A IN2012DN03294 A IN 2012DN03294A IN 3294DEN2012 A IN3294DEN2012 A IN 3294DEN2012A IN 2012DN03294 A IN2012DN03294 A IN 2012DN03294A
Authority
IN
India
Prior art keywords
epitope
candidate
cross
binding agent
specific binding
Prior art date
Application number
Inventor
J Chang Gwongjen
D Crill Wayne
Original Assignee
Government Of The Us Secretary Of The Dept Of Health And Human Services Ct S For Disease Control And
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of The Us Secretary Of The Dept Of Health And Human Services Ct S For Disease Control And filed Critical Government Of The Us Secretary Of The Dept Of Health And Human Services Ct S For Disease Control And
Publication of IN2012DN03294A publication Critical patent/IN2012DN03294A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

An in vitro method for identifying a flavivirus cross-reactive epitope, comprising selecting a candidate cross-reactive epitope using a structure-based design approach, wherein the structure-based design approach, designing a substituted epitope comprising at least one amino acid residue substitution compared to the candidate cross-reactive epitope; contacting the candidate cross-reactive epitope with a specific binding agent under conditions whereby a candidate epitope/specific binding agent complex can form; and contacting the substituted epitope with the specific binding agent under the same conditions used for candidate epitope/specific binding agent complex formation, wherein a candidate cross-reactive epitope is identified as the fiavivirus cross-reactive epitope when the substituted epitope has a substantially lower binding affinity for the specific binding agent compared to the candidate cross-reactive epitope.
IN3294DEN2012 2004-07-27 2005-07-27 IN2012DN03294A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59189804P 2004-07-27 2004-07-27
PCT/US2005/026672 WO2006025990A2 (en) 2004-07-27 2005-07-27 Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use

Publications (1)

Publication Number Publication Date
IN2012DN03294A true IN2012DN03294A (en) 2015-10-23

Family

ID=36000491

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3294DEN2012 IN2012DN03294A (en) 2004-07-27 2005-07-27

Country Status (6)

Country Link
US (3) US7906292B2 (en)
EP (1) EP1784487B1 (en)
AT (1) ATE521627T1 (en)
CA (1) CA2576798C (en)
IN (1) IN2012DN03294A (en)
WO (1) WO2006025990A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3150430A1 (en) 2009-07-31 2011-02-03 Pnuvax Inc. High yield yellow fever virus strain with increased propagation in cells
WO2013009884A1 (en) * 2011-07-12 2013-01-17 The Government Of The United States America As Represented By The Secretary Of The Department Of Health And Human Services Identification of a west nile virus cd4 t cell epitope and use thereof
WO2013059493A1 (en) * 2011-10-20 2013-04-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
WO2014064943A1 (en) * 2012-10-25 2014-05-01 Osaka University Antigenic peptide derived from dengue virus
CN110734500A (en) 2013-06-26 2020-01-31 北卡罗来纳-查佩尔山大学 Methods and compositions for dengue virus vaccines
US10060924B2 (en) 2014-03-18 2018-08-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Distinguishing flavivirus infection using a recombinant mutant envelope protein
WO2016130321A1 (en) * 2015-02-09 2016-08-18 Academia Sinica An epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
US11007260B2 (en) 2015-07-21 2021-05-18 Modernatx, Inc. Infectious disease vaccines
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
GB201610162D0 (en) * 2016-06-10 2016-07-27 Imp Innovations Ltd And Inst Pasteur Methods
US10947277B2 (en) 2016-06-13 2021-03-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays
WO2018052549A1 (en) 2016-09-19 2018-03-22 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Zika virus vaccines
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. High potency immunogenic compositions
WO2018152526A1 (en) 2017-02-20 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Zika virus vaccines
GB201704126D0 (en) * 2017-03-15 2017-04-26 Blom Nihlén Kim Andrea Vaccine
MA50253A (en) 2017-09-14 2020-07-22 Modernatx Inc ZIKA VIRUS RNA VACCINES
CN111048154B (en) * 2019-12-10 2023-06-06 上海药明生物技术有限公司 Method for mapping antibody epitope
WO2022074111A1 (en) * 2020-10-07 2022-04-14 Sanofi Pasteur Improved diagnostic tests
WO2023178310A1 (en) * 2022-03-17 2023-09-21 The University Of North Carolina At Chapel Hill Compositions comprising modified flavivirus e glycoproteins and methods of making and using the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK172110B1 (en) * 1988-04-15 1997-10-27 Gen Hospital Corp Method for Isolating Mutants of DNA Sequences and Their Use in Identifying Cell Surface Proteins
US6074865A (en) * 1995-07-20 2000-06-13 The United States Of America As Represented By The Secretary Of The Army Recombinant dengue virus DNA fragment
AU4556597A (en) 1996-09-24 1998-04-17 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
CU22683A1 (en) 1997-01-15 2001-07-20 Inst De Medicina Tropical Pedro Kouri EPITHES OF THE PRE-M / M PROTEIN OF THE DENGUE VIRUS, SYNTHETIC PEPTIDES, CHEMICAL PROTEINS AND THEIR USES
BRPI9701774B8 (en) 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz mutant and infectious yellow fever virus cdna, DNA construct, recombinant yellow fever virus and human vaccine against yellow fever infections.
AU778988B2 (en) 1998-06-04 2004-12-23 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Nucleic acid vaccines for prevention of flavivirus infection
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
CA2548808C (en) * 2003-12-08 2015-07-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus

Also Published As

Publication number Publication date
US20150246951A1 (en) 2015-09-03
US9000141B2 (en) 2015-04-07
EP1784487A2 (en) 2007-05-16
ATE521627T1 (en) 2011-09-15
US7906292B2 (en) 2011-03-15
US20080248064A1 (en) 2008-10-09
WO2006025990A3 (en) 2006-06-29
US20110059131A1 (en) 2011-03-10
US9650422B2 (en) 2017-05-16
CA2576798C (en) 2014-09-09
EP1784487B1 (en) 2011-08-24
CA2576798A1 (en) 2006-03-09
WO2006025990A2 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
IN2012DN03294A (en)
ZA200803012B (en) Bitumen composition
TW200701019A (en) Device specific content indexing for optimized device operation
MX348414B (en) Placental stem cell populations.
NZ581470A (en) Sequence based engineering and optimization of single chain antibodies
TW200714294A (en) Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
EP1553975A4 (en) Optimized fc variants and methods for their generation
TW200727791A (en) Materials and methods for improving livestock productivity
WO2006134190A3 (en) Agents and methods based on the use of the eda domain of fibronectin
GT200600087A (en) FERRONÍQUEL PRODUCTION
EP1843788A4 (en) Glp-1 agonists, compositions, methods and uses
TW200723252A (en) Information processing device, information recording medium manufacturing device, information recording medium, methods thereof, and computer program
WO2005116252A3 (en) Methods for evaluating ribonucleotide sequences
WO2006135793A3 (en) Protein engineering with analogous contact environments
AU2019268061A1 (en) Placental stem cell populations
ATE500503T1 (en) CD86 AND CD80 RECEPTOR COMPETITION TESTS
EP1869468A4 (en) Colloidal metal conjugates
MX2010000979A (en) Methods and compositions for treating autoimmune disease.
MY142401A (en) Materials and methods for improving shellfish heatlh, immunity and growth
MX2008009830A (en) Bst2 inhibitor.
WO2005000876A3 (en) Ring finger family proteins and uses related thereto
IL191782A0 (en) Method for generating dendritic cells employing decreased temperature
EA200970074A1 (en) CHEMICAL METHOD FOR CREATING PRESSURE
TW200619281A (en) Method for preparation of polyolefin nanocomposite
GB2412921A (en) Process for the preparation of and composition of a feedstock usable for the preparation of lower olefins